Abstract
There were good clinical outcomes of drug-eluting balloon (DEB) use in de novo lesions and in-stent restenosis (ISR) lesions. However, few studies focused on DEB use in patients with acute myocardial infarction (AMI). The aim of this study was to retrospective evaluate the efficacy of DEB for patients of AMI with de novo small coronary artery disease. Between March 2016 and March 2018, patients of AMI with de novo small coronary artery (reference diameter 2.0–2.8 mm) and received percutaneous coronary intervention (PCI) were enrolled. 268 patients were divided into DEB group (PCI with further DEB, n = 56) and drug-eluting stent (DES) group (PCI with further DES, n = 212). The primary endpoint was major adverse cardiac events (MACE; all-cause death, non-fatal myocardial infarction, target lesion revascularization and target vessel revascularization) at 24 months. A subset of patients underwent angiographic follow-up. Clinical characteristics were balanced in the two groups. Mean reference vessel diameter was similar between the DEB and DES groups (2.64 ± 0.17 mm vs 2.65 ± 0.14 mm, P = 0.625). The 24-month MACE rates were 17.5% in DEB group and 16.4% in DES group (P = 0.853). Stent thrombosis was seen in three patients (1.46%) in DES group. There was no vessel thrombosis noted in the DEB group. Angiographic follow-up was performed in 35.71% of DEB group and 27.25% of DES group. Late lumen loss was similar between the two groups (DEB 0.14 ± 0.13 mm, DES 0.19 ± 0.12 mm, P = 0.442). DEB is a reasonable strategy for AMI with small coronary artery. Compared with DES, DEB is an alternative strategy which had similar 24-month clinical outcomes.
Similar content being viewed by others
References
Ismail MD, Ahmad WAW, Leschke M, Waliszewski M, Boxberger M, Abidin IZ et al (2016) The outcomes of patients with very small coronary artery disease treated with thin strut cobalt chromium bare metal stents: an observational study. Springerplus 5(1):1668
Mohiaddin H, Wong TD, Burke-Gaffney A, Bogle RG (2018) Drug-coated balloon-only percutaneous coronary intervention for the treatment of de novo coronary artery disease: a systematic review. Cardiol Ther 7:127–149
Worthley S, Hendriks R, Worthley M, Whelan A, Walters D, Whitbourn R et al (2015) Paclitaxel-eluting balloon and everolimus-eluting stent for provisional stenting of coronary bifurcations: 12-month results of the multicenter BIOLUX-I study. Cardiovasc Revasc Med 16:413–417
Besic KM, Strozzi M, Margetic E, Bulum J, Kolaric B (2015) Drug-eluting balloons in patients with non-ST elevation acute coronary syndrome. J Cardiol 65:203–207
Baan J, Claessen BE, Dijk KB, Vendrik J, van der Schaaf RJ, Meuwissen M et al (2018) A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis. The DARE trial. J Am Coll Cardiol Interv 11:275–283
Kufner S, Cassese S, Valeskini M, Neumann F, Schulz-Schüpke S, Hoppmann P et al (2015) Long-term efficacy and safety of paclitaxel-eluting balloon for the treatment of drug-eluting stent restenosis 3-year results of a randomized controlled trial. J Am Coll Cardiol Interv 8:877–884
Alfonso F, Pérez-Vizcayno MJ, Cuesta J, del Blanco BG, García-Touchard A, López-Mínguez JR et al (2018) 3-Year clinical follow-up of the ribs iv clinical trial: a prospective randomized study of drug-eluting balloons versus everolimus eluting stents in patients with in-stent restenosis in coronary arteries previously treated with drug-eluting stents. J Am Coll Cardiol Interv 11:981–991
Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, Felice F et al (2012) A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels. The BELLO (Balloon Elution and Late Loss Optimization) study. JACC 60(24):2473–2480
Giannini F, Latib A, Jabbour RJ, Costopoulos C, Chieffo A, Carlino M et al (2017) Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients—results from the BELLO (balloon elution and late loss optimization) trial. Cardiovasc Revascul Med 18(1):4–9
Sinaga DA, Ho HH, Watson TJ, Sim A, Nyein TT, Jafary FH et al (2016) Drug-coated balloons: a safe and effective alternative to drug-eluting stents in small vessel coronary artery disease. J Interv Cardiol 29(5):454–460
Tan Q, Wang QS, Liu DT, Zhang SY, Zhang Y, Li Y (2015) Intravascular ultrasound-guided unprotected left main coronary artery stenting in the elderly. Saudi Med J 36(5):549–553
Picard F, Doucet S, Asgar AW (2017) Contemporary use of drug-coated balloons in coronary artery disease: where are we now? Arch Cardiovasc Dis 110(4):259–272
Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al (2019) 2018 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention 14(14):1435–1534
Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S et al (2010) Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 96(16):1291–1296
Sim HW, Ananthakrishna R, Chan SP, Low AF, Lee CH, Chan MY et al (2018) Treatment of very small de novo coronary artery disease with 2.0 mm drug-coated balloons showed 1-year clinical outcome comparable with 2.0 mm drug-eluting stents. J Invasive Cardiol 30(7):256–261
Belkacemi A, Agostoni P, Nathoe HM, Voskuil M, Shao C, Van Belle E et al (2012) First results of the DEBAMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicentre randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. J Am Coll Cardiol 59:2327–2337
Fang CY, Fang HY, Chen CJ, Yang CH, Wu CJ, Lee WC (2018) Comparison of clinical outcomes after drug-eluting balloon and drugeluting stent use for in-stent restenosis related acute myocardial infarction: a retrospective study. PeerJ 15(6):e4646
Vos NS, Fagel ND, Amoroso G, Herrman JR, Patterson MS, Piers LH et al (2019) Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction: the REVELATION randomized trial. JACC Cardiovasc Interv 12(17):1691–1699
Funding
This study was supported by Hebei medical technology project (20171252) and Qinhuangdao technology supporting project (201801B032).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest statement.
Statement of human and animal rights
This study was approved by the ethics committee of Qinhuangdao First Hospital. This study was carried out conforming to the principles expressed in the Declaration of Helsinki.
Informed consent
For this type of study, formal consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tan, Q., Wang, Q., Yang, H. et al. Clinical outcomes of drug-eluting balloon for treatment of small coronary artery in patients with acute myocardial infarction. Intern Emerg Med 16, 913–918 (2021). https://doi.org/10.1007/s11739-020-02530-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-020-02530-w